Compounds > 4-benzyloxybenzoic acid
Page last updated: 2024-12-06

4-benzyloxybenzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Benzyloxybenzoic acid is a white crystalline solid that is commonly used as an intermediate in the synthesis of various organic compounds. It is also known to exhibit anti-inflammatory and analgesic properties. Its synthesis is typically achieved through a multi-step process involving the reaction of 4-hydroxybenzoic acid with benzyl chloride in the presence of a base. The compound is studied for its potential applications in the pharmaceutical and materials science fields. Its anti-inflammatory and analgesic properties make it a promising candidate for the development of novel drugs for the treatment of inflammatory conditions. The compound's structural features also make it an attractive building block for the synthesis of new materials with unique properties.'

4-benzyloxybenzoic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73880
CHEMBL ID3134411
CHEBI ID194624
SCHEMBL ID228477
MeSH IDM0065035

Synonyms (56)

Synonym
BB 0245700
4-benzyloxy-benzoic acid
OPREA1_723890
1486-51-7
nsc16633
nsc-16633
benzoic acid, 4-(phenylmethoxy)-
4-benzyloxybenzoic acid
4-(benzyloxy)benzoic acid
STK082711
inchi=1/c14h12o3/c15-14(16)12-6-8-13(9-7-12)17-10-11-4-2-1-3-5-11/h1-9h,10h2,(h,15,16
SR-01000633233-1
4-benzyloxybenzoic acid, 99%
brl 14280
b1665 ,
AKOS000109246
4-phenylmethoxybenzoic acid
CHEBI:194624
4-benzyloxybenzoate
A808796
BBL008036
4-benzyloxy benzoic acid
4-(phenylmethoxy)benzoic acid
CCG-43304
unii-4k45h4g7kp
einecs 216-066-0
p-(benzyloxy)benzoic acid
brl-14280
nsc 16633
4k45h4g7kp ,
FT-0617664
MS-1799
SCHEMBL228477
CHEMBL3134411 ,
4benzyloxybenzoic acid
4-carboxyphenoxy-phenyl methane
p-benzyloxybenzoic acid
4-(benzyloxy)-benzoic acid
4 - carboxyphenoxy - phenyl methane
4-carboxyphenoxy phenyl methane
p-(benzyloxy)benzoicacid
DTXSID00164030
CS-W005179
mfcd00016527
J-008502
Z56869319
F3146-0159
4-(benzyloxy)benzoicacid
BCP24385
SY004155
4-benzyloxybenzoicacid
bdbm50496605
EN300-17060
BRD-K00030946-001-01-7
Q27449797
CK2186
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1077997Inhibition of Escherichia coli DNA gyrase-mediated DNA relaxation by agarose gel electrophoresis2013MedChemComm, Dec-01, Volume: 4, Issue:12
Synthesis and antibacterial evaluation of anziaic acid and analogues as topoisomerase I inhibitors.
AID1149891Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum triglyceride level at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149912Hypolipidemic activity in CFY Sprague-Dawley rat assessed as liver lipid per gm of liver at 0.2% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149893Toxicity in CFY Sprague-Dawley rat assessed as relative liver weight at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149900Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum triglyceride level at 0.2% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149896Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum cholesterol level at 0.2% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1077999Antibacterial activity against Bacillus subtilis BAS3023 assessed as complete growth inhibition after 24 hrs by standard microdilution assay2013MedChemComm, Dec-01, Volume: 4, Issue:12
Synthesis and antibacterial evaluation of anziaic acid and analogues as topoisomerase I inhibitors.
AID1149902Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum triglyceride level at 1% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149890Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum cholesterol level at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149910Toxicity in CFY Sprague-Dawley rat assessed as relative liver weight at 1% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1078000Inhibition of human topoisomerase 2 alpha-mediated relaxation of supercoiled plasmid DNA by agarose gel electrophoresis2013MedChemComm, Dec-01, Volume: 4, Issue:12
Synthesis and antibacterial evaluation of anziaic acid and analogues as topoisomerase I inhibitors.
AID1078001Inhibition of Yersinia pestis topoisomerase 1-mediated relaxation of supercoiled plasmid DNA by agarose gel electrophoresis2013MedChemComm, Dec-01, Volume: 4, Issue:12
Synthesis and antibacterial evaluation of anziaic acid and analogues as topoisomerase I inhibitors.
AID1149914Hypolipidemic activity in CFY Sprague-Dawley rat assessed as liver lipid per gm of liver at 1% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149898Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum cholesterol level at 1% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149894Hypolipidemic activity in CFY Sprague-Dawley rat assessed as liver lipid per gm of liver at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149908Toxicity in CFY Sprague-Dawley rat assessed as relative liver weight at 0.2% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149918Inhibition of fatty acid biosynthesis from [1-14C]acetate in rat liver slices at 5 X 10'-4 M relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149906Toxicity in CFY Sprague-Dawley rat assessed as body weight gain at 1% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149904Toxicity in CFY Sprague-Dawley rat assessed as body weight gain at 0.2% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149915Inhibition of cholesterol biosynthesis from [1-14C]acetate in rat liver slices at 5 X 10'-4 M relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1077998Antibacterial activity against Escherichia coli assessed as complete growth inhibition after 24 hrs by standard microdilution assay2013MedChemComm, Dec-01, Volume: 4, Issue:12
Synthesis and antibacterial evaluation of anziaic acid and analogues as topoisomerase I inhibitors.
AID1149892Toxicity in CFY Sprague-Dawley rat assessed as body weight gain at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacin
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.		1.9510pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
am 580
Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source. 4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.		2.0810amidobenzoic acid;
tetralins		antineoplastic agent;
retinoic acid receptor alpha/beta agonist
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		1.9510aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
2-phenylbutyric acid
2-phenylbutyric acid : A monocarboxylic acid that is butyric acid substituted by a phenyl group at position 2.		1.9510benzenes;
monocarboxylic acid		human xenobiotic metabolite
proadifen hydrochloride
[no description available]		1.9510
benzylvanillin
benzylvanillin: structure given in first source		1.9510
tamibarotene
tamibarotene: has retinoid-binding activity. tamibarotene : A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine.		2.0810dicarboxylic acid monoamide;
retinoid;
tetralins		antineoplastic agent;
retinoic acid receptor alpha/beta agonist
olivetolic acid
olivetolic acid: structure in first source. olivetolic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogens ortho- and para- to the carboxy group are replaced by a pentyl and a hydroxy group, respectively.		2.0810benzoic acids;
monocarboxylic acid;
polyketide;
resorcinols		metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9510
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310